2022
Comparison of Pharmacy Refill Data With Chemical Adherence Testing in Assessing Medication Nonadherence in a Safety Net Hospital Setting
Osula D, Wu B, Schesing K, Das SR, Moss E, Alvarez K, Clark C, Halm EA, Brown NJ, Vongpatanasin W. Comparison of Pharmacy Refill Data With Chemical Adherence Testing in Assessing Medication Nonadherence in a Safety Net Hospital Setting. Journal Of The American Heart Association 2022, 11: e027099. PMID: 36193931, PMCID: PMC9673714, DOI: 10.1161/jaha.122.027099.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsCalcium Channel BlockersCross-Sectional StudiesHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypertensionMedication AdherencePharmacySafety-net ProvidersSodium Chloride Symporter InhibitorsConceptsEnzyme inhibitors/angiotensin receptor blockersAngiotensin receptor blockersCalcium channel blockersReceptor blockersPositive predictive valueUncontrolled hypertensionBeta blockersMedication nonadherenceAntihypertensive drugsDrug classesChannel blockersAngiotensin-converting enzyme inhibitors/angiotensin receptor blockersPredictive valueAdherence testingSafety-net hospital settingSafety-net health systemLow positive predictive valuePharmacy refill dataProportion of daysCross-sectional studyPlasma drug levelsDiagnostic test characteristicsPharmacy fill dataCommon cardiovascular drugsRefill data
2018
Characteristics and treatment of African-American and European-American patients with resistant hypertension identified using the electronic health record in an academic health centre: a case−control study
Shuey MM, Gandelman JS, Chung CP, Nian H, Yu C, Denny JC, Brown NJ. Characteristics and treatment of African-American and European-American patients with resistant hypertension identified using the electronic health record in an academic health centre: a case−control study. BMJ Open 2018, 8: e021640. PMID: 29950471, PMCID: PMC6020960, DOI: 10.1136/bmjopen-2018-021640.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAdultAgedAngiotensin Receptor AntagonistsAntihypertensive AgentsBlack or African AmericanBlood PressureCalcium Channel BlockersCase-Control StudiesDiabetes Mellitus, Type 2Electronic Health RecordsFemaleHumansHypertensionLogistic ModelsMaleMiddle AgedMultivariate AnalysisPrevalenceTennesseeWhite PeopleConceptsElectronic health recordsResistant hypertensionBlood pressureChronic kidney disease stage 3Mineralocorticoid receptor antagonist useClinical treatmentDihydropyridine calcium channel blockerAntihypertensive medication classesControlled blood pressureOutpatient blood pressureTotal hypertensive populationAngiotensin receptor blockersTransient ischemic attackDisease stage 3Health recordsMineralocorticoid receptor antagonistsReceptor antagonist useHigh blood pressureIschemic heart diseaseAlpha-2 agonistsBody mass indexCalcium channel blockersAfrican American patientsNumber of patientsType 2 diabetes
2012
Differential Effects of Nebivolol and Metoprolol on Insulin Sensitivity and Plasminogen Activator Inhibitor in the Metabolic Syndrome
Ayers K, Byrne LM, DeMatteo A, Brown NJ. Differential Effects of Nebivolol and Metoprolol on Insulin Sensitivity and Plasminogen Activator Inhibitor in the Metabolic Syndrome. Hypertension 2012, 59: 893-898. PMID: 22353614, PMCID: PMC3402551, DOI: 10.1161/hypertensionaha.111.189589.Peer-Reviewed Original ResearchConceptsEffects of nebivololMetabolic syndromeBlood pressureInsulin sensitivityPlasminogen activator inhibitorAntagonist metoprololGlucose homeostasisThird-generation β-blockerActivator inhibitorMarkers of fibrinolysisCongestive heart failureDiastolic blood pressureLower blood pressureSystolic blood pressureCoronary artery diseaseGlucose tolerance testLarge clinical trialsDetrimental metabolic effectsPlasminogen activator inhibitor-1Insulin sensitivity indexAcute insulin responseΒ-cell functionActivator inhibitor-1Study drugArtery disease
2001
Preprescription Genotyping
Roden D, Brown N. Preprescription Genotyping. Circulation 2001, 103: 1608-1610. PMID: 11273984, DOI: 10.1161/01.cir.103.12.1608.Peer-Reviewed Original Research
2000
Endogenous bradykinin and the renin and pressor responses to furosemide in humans.
Murphey LJ, Kumar S, Brown NJ. Endogenous bradykinin and the renin and pressor responses to furosemide in humans. Journal Of Pharmacology And Experimental Therapeutics 2000, 295: 644-8. PMID: 11046100.Peer-Reviewed Original ResearchConceptsPlasma renin activityMean arterial pressureHoe 140Renin responseEndogenous bradykininRenin activityArterial pressureHeart rateBasal plasma renin activityRenin-angiotensin systemAngiotensin I/Blood pressure regulationCrossover design studyAcute furosemide treatmentRenin regulationSpecific bradykininDiuretic responseFurosemide administrationFurosemide treatmentACE inhibitionReceptor antagonistPressure regulationBradykininFurosemideHumansBradykinin Stimulates Tissue Plasminogen Activator Release From Human Forearm Vasculature Through B2 Receptor–Dependent, NO Synthase–Independent, and Cyclooxygenase-Independent Pathway
Brown N, Gainer J, Murphey L, Vaughan D. Bradykinin Stimulates Tissue Plasminogen Activator Release From Human Forearm Vasculature Through B2 Receptor–Dependent, NO Synthase–Independent, and Cyclooxygenase-Independent Pathway. Circulation 2000, 102: 2190-2196. PMID: 11056091, DOI: 10.1161/01.cir.102.18.2190.Peer-Reviewed Original ResearchMeSH Keywords6-Ketoprostaglandin F1 alphaAcetylcholineAdrenergic beta-AntagonistsAdultBradykininBradykinin Receptor AntagonistsCyclooxygenase InhibitorsEndothelium, VascularFemaleForearmHumansIndomethacinInfusions, Intra-ArterialMaleNitric Oxide SynthaseNitroprussideOmega-N-MethylargininePlethysmographyReceptor, Bradykinin B2Regional Blood FlowTissue Plasminogen ActivatorVasodilationVasodilator AgentsConceptsTissue plasminogen activator releaseVasodilator responseL-NMMAPlasminogen activator releaseCyclooxygenase-independent pathwayTPA releaseActivator releaseBasal forearm blood flowReceptor antagonist HOE 140NO synthase inhibitor LHuman endotheliumHuman forearm vasculatureForearm blood flowEffect of indomethacinIntra-arterial bradykininReceptor-dependent effectsCyclooxygenase inhibitor indomethacinMonomethyl-L-arginineForearm vasodilationEndothelial effectsIndomethacin administrationForearm vasculatureHoe 140Receptor antagonismUrinary excretion
1998
Effect of Bradykinin-Receptor Blockade on the Response to Angiotensin-Converting–Enzyme Inhibitor in Normotensive and Hypertensive Subjects
Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ. Effect of Bradykinin-Receptor Blockade on the Response to Angiotensin-Converting–Enzyme Inhibitor in Normotensive and Hypertensive Subjects. New England Journal Of Medicine 1998, 339: 1285-1292. PMID: 9791144, DOI: 10.1056/nejm199810293391804.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBlood PressureBradykininBradykinin Receptor AntagonistsCaptoprilDiet, Sodium-RestrictedDrug InteractionsDrug Therapy, CombinationFemaleHumansHypertensionKidneyLosartanMaleReference ValuesRenin-Angiotensin SystemSingle-Blind MethodConceptsPlasma renin activityBlood pressureACE inhibitionHypertensive subjectsShort-term effectsRenin activitySpecific bradykinin receptor antagonistAngiotensin converting enzyme (ACE) inhibitorsAdministration of captoprilAdministration of losartanBradykinin receptor blockadeCoadministration of icatibantContribution of bradykininRenal hemodynamic responseNormal blood pressureRenin-angiotensin systemSeparate study daysBradykinin receptor antagonistDegradation of bradykininAntagonist losartanHypertensive personsHypotensive effectAngiotensin IIAngiotensin-ConvertingHemodynamic response